Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Better Therapeutics, Inc. BTTX
$0.80
+$0.01 (1.78%)
На 18:04, 12 мая 2023
+2 025.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
26178158.00000000
-
week52high
2.80
-
week52low
0.59
-
Revenue
0
-
P/E TTM
0
-
Beta
1.45355500
-
EPS
-1.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 29 июл 2022 г. |
| Chardan Capital | Buy | Buy | 16 мар 2022 г. |
| Chardan Capital | Buy | 24 ноя 2021 г. | |
| Cowen & Co. | Outperform | 10 ноя 2021 г. | |
| Chardan Capital | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Heinen Mark | A | 85723 | 15723 | 30 ноя 2022 г. |
| Wynholds Kristin | A | 98819 | 3781 | 30 ноя 2022 г. |
| PERRY DAVID P | A | 101536 | 39156 | 16 сент 2022 г. |
| PERRY DAVID P | A | 62380 | 10844 | 15 сент 2022 г. |
| KARBE FRANK | A | 50000 | 50000 | 15 сент 2022 г. |
| Heinen Mark | A | 70000 | 26132 | 13 сент 2022 г. |
| Heinen Mark | A | 43868 | 23868 | 12 сент 2022 г. |
| KARBE FRANK | A | 472200 | 472200 | 05 июл 2022 г. |
| Heinen Mark | A | 2281 | 2281 | 24 июн 2022 г. |
| Armanino Andrew J. | A | 15000 | 15000 | 14 июн 2022 г. |
Новостная лента
Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 22:27
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
14 авг 2022 г. в 06:34
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Why Is Better Therapeutics (BTTX) Stock Up 27% Today?
InvestorPlace
28 июл 2022 г. в 11:10
Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
Business Wire
26 июл 2022 г. в 07:30
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen
3 Penny Stocks That Have Huge Catalysts Ahead
InvestorPlace
27 июн 2022 г. в 19:45
While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.